Telix Pharmaceuticals Shares Hit A Wall of Resistance: What Happened?

Telix Pharmaceuticals shares (ASX: TLX) were the second worst performer on the ASX 200 on Friday, sliding double digits into the weekend despite delivering a solid half-year result that beat revenue expectations and showed continued momentum in its precision medicine franchise. With TLX having been met with resistance at the A$17.35-$17.40 price zone three times in the past two months, a triple top setup does not read well on the chart for bulls.

The Telix share price closed down 10.13% at A$15.62 on Friday, capping a double-digit decline over the trading session that erased what had been shaping up to be a solid week for holders. The pullback came just one day after the company reported its HY26 results, catching many off guard given the solid print, and initial positive reaction.

The stock had enjoyed a substantial rally since the start of this year, yet the sector gave back some gains ahead of the weekend, with TLX ‘leading’ the way. CSL shares were 1.69% lower, 4DMedical shares fell 4.73%, and Pro Medicus shares gave back 6.99%, leaving sector bulls looking for some answers into week ahead.

Strong Fundamentals Meet Lofty Expectations

The numbers Telix reported for the six months to 30 June 2026 were strong, as revenue climbed 22% year-on-year to US$477 million, putting the company on track to hit the upper end of its full-year guidance range of US$950 million to US$970 million.

Gross margin improved to 55%, up approximately two percentage points from the prior year, while the higher-margin Precision Medicine segment delivered a 65% margin. The margin expansion reflects improving operating leverage as Telix scales its manufacturing and supply chain infrastructure, a key milestone for a company transitioning from pure growth mode toward sustainable profitability.

Adjusted EBITDA came in at US$52 million, up 146% on the prior corresponding period. However, that figure included a US$40 million upfront payment from Regeneron Pharmaceuticals as part of a strategic collaboration agreement. Stripping out that non-recurring item, the underlying EBITDA performance was more modest, highlighting the company’s continued heavy investment phase.

Profit after tax reached US$38 million, effectively equivalent to the Regeneron payment, which implies the underlying business is operating near breakeven after accounting for the group’s US$124 million research and development spend during the half. That R&D investment, focused primarily on late-stage clinical programs, represents a deliberate strategic choice to fund multiple pipeline shots on goal, but it also means near-term earnings remain sensitive to any revenue volatility.

On the balance sheet, Telix reported positive operating cash flow of US$23 million and a cash balance of US$252 million as at 30 June 2026. The cash position provides a comfortable runway to fund ongoing trials and commercial expansion without immediate need for dilutive capital raising, a key concern that often weighs on biotech valuations.

Management reiterated full-year guidance and indicated that total revenue plus other income should exceed US$1 billion for FY26, with revenue itself tracking near the top of the previously announced range.

Valuation Debate Continues

One particular point of focus on the day appears to have been a research note from Bell Potter, one of Telix’s long-time supporters, which downgraded the stock from Buy to Hold while maintaining a price target of A$19.00. The broker’s rationale pointed to valuation, effectively saying that after a strong run, the shares are now approaching fair value, making the risk-reward profile more balanced.

Bell Potter’s move does not signal a loss of confidence in Telix’s long-term thesis. The A$19.00 target still implies meaningful upside from Friday’s closing price, and the broker’s historical approach has been to downgrade on valuation grounds even when the operational outlook remains constructive. However, the optics of a downgrade on the day after results contributed to selling that was already taking place in the sector, particularly among momentum-oriented investors who had positioned for a more enthusiastic broker response.

Telix’s valuation has been a point of contention throughout its commercial phase. Bulls point to the company’s expanding portfolio of approved radiopharmaceutical products, its growing geographic footprint, and the potential for multiple additional indications to drive sustained double-digit revenue growth for years to come. They draw comparisons to CSL Limited in its early commercial phase, arguing that Telix is building a rare, durable platform in a high-barrier segment of oncology and urology.

Bears counter that the stock still trades on growth and pipeline optionality rather than mature pharmaceutical multiples, leaving it vulnerable to any disappointment or sector-wide de-rating. The heavy ongoing R&D spend and capital requirements for manufacturing infrastructure mean free cash flow generation remains modest relative to the market capitalisation, and valuation remains sensitive to changes in discount rates and risk appetite.

The deceleration in revenue growth from over 50% in FY25 to 22% in HY26, while still impressive, feeds the narrative that Telix may be entering a more mature growth phase. Markets have shown limited patience for “good but not great” prints from high-multiple growth stocks, particularly in the current macro environment where rising rates and tighter liquidity are pressuring speculative positioning.

Partnership Validation

One unambiguously positive element of the HY26 result was the Regeneron collaboration and its associated US$40 million upfront payment. The deal represents external validation of Telix’s radiopharmaceutical platform by a major pharmaceutical company with deep expertise in oncology and biologics. While the financial contribution is non-recurring, the strategic signal is important: it suggests Telix is viewed as more than a single-asset story and that its technology platform has applications beyond its current commercial products.

Partnerships of this nature can also provide non-financial benefits, including access to Regeneron’s clinical development expertise, regulatory pathways, and commercial infrastructure in key markets. For a company still building out its own capabilities, such collaborations can accelerate timelines and reduce execution risk on pipeline assets.

Looking Ahead

Price Targets

Telix’s immediate focus will be on delivering the second half performance needed to hit full-year guidance and on advancing its late-stage pipeline programs toward regulatory milestones. The company has several potential catalysts on the horizon, including data readouts from ongoing trials, additional geographic approvals for existing products, and the possibility of further partnership announcements.

From a valuation perspective, Telix shares are not obviously cheap after its strong run, but not overly expensive if the growth trajectory and pipeline execution continue as planned. The latest price targets on the stock continue to point to a healthy potential upside, but with plenty now priced in, and what could be a triple top on the charts in the upper A$17.30’s, the caution into the weekend will need to be met with buyers willing to step in at these levels if a breakout is to materialise.

Bull Case: